search
Back to results

Intestinal Microbiome-based Research for the Prevention of Acute GVHD

Primary Purpose

Graft Versus Host Disease, Postbiotics, Butyrate

Status
Recruiting
Phase
Phase 2
Locations
Korea, Republic of
Study Type
Interventional
Intervention
sodium butyrate
Sponsored by
Soonchunhyang University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Graft Versus Host Disease focused on measuring butyrate, Graft Versus Host Disease, postbiotics

Eligibility Criteria

19 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients undergoing hematopoietic stem cell transplantation Adult patients over 19 years and under 70 of age Exclusion Criteria: Patients who did not agree to participate in the study If feces are not suitable for analysis

Sites / Locations

  • Soonchunhyang University Seoul HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Butyrate

Arm Description

Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭ per day)

Outcomes

Primary Outcome Measures

Incidence of GVHD

Secondary Outcome Measures

Full Information

First Posted
January 27, 2023
Last Updated
April 11, 2023
Sponsor
Soonchunhyang University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05808985
Brief Title
Intestinal Microbiome-based Research for the Prevention of Acute GVHD
Official Title
Intestinal Microbiome-based Research for the Prevention of Acute Graft-versus-host Disease
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 2, 2022 (Actual)
Primary Completion Date
September 30, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Soonchunhyang University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Hematopoietic stem cell transplantation consists of preconditioning chemotherapy, stem cell infusion, and engraftment of hematopoietic stem cells. In this process, in the case of recipients who receive hematopoietic stem cells, their immune system is completely destroyed and then undergoes a situation in which it is reconstituted. In this process, the diversity of the intestinal microbiome is reduced, and it is widely known that a severe decrease is associated with the occurrence of an acute graft-versus-host reaction. Attempts to improve the intestinal microbiome include prebiotics, probiotics, and postbiotics. Prebiotics can be expected to improve the intestinal microbiome by acting as nutrients for beneficial bacteria in the intestine, but their role may be limited in situations where the diversity of the intestinal microbiome has already decreased. Probiotics are a method to expect improvement of the intestinal microbiome by administering the beneficial bacteria themselves in the intestine, but there is a difficulty in reaching the intestine properly through stomach acid, and there is a risk of causing sepsis in immunocompromised patients. Postbiotics is a product that beneficial bacteria metabolize and release prebiotics in the intestine, and the microbiome in the intestine is actually responsible for the function that affects the human body. Therefore, in this study, postbiotics are administered to patients undergoing hematopoietic stem cell transplantation who are concerned that the diversity of the intestinal microbiome may have already decreased, to improve the intestinal microbiome and hope to prevent graft-versus-host reactions through this. Furthermore, it is intended to improve the outcome of allogeneic hematopoietic stem cell transplantation.
Detailed Description
step After explaining the background and purpose of the study to the subjects undergoing hematopoietic stem cell transplantation at Soonchunhyang University Seoul Hospital and obtaining consent, before transplantation (D-7), on the day of transplantation (D0), and at the time of engraftment after transplantation (D+ 14), 30 days after transplantation (D+30), 3 months after transplantation (D+90), if complications occur after a total of 5 times, if the researcher deems it necessary, with the consent of the patient, additional feces are collected. About 10g per dose will be received and stored in a freezer at the Institute of Clinical Molecular Biology, Soonchunhyang University until December 2027, and DNA will be extracted and microbiome analyzed later, and discarded at the end of the study. In the process of allogeneic hematopoietic stem cell transplantation, the subjects had difficulty in oral intake during the transplantation process after pretreatment chemotherapy, so at the time of engraftment oral intake was possible, starting to take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭) for 3 months after transplantation Continue taking until All expenses incurred in the course of testing are borne by the researcher. The patient's clinical progress and test results related to hematopoietic stem cell transplantation are investigated based on medical records. Duration of subject participation and expected number of subjects For patients undergoing hematopoietic stem cell transplantation at our hospital from the date of IRB approval to December 2023 (About 20 patients a year receive hematopoietic stem cell transplantation at our center, and it is expected that about 30 patients will participate) Clinical Study Restrictions and Subject Obligations Subjects who agreed to the study must take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭) from the time of engraftment to 3 months after transplantation, and must collect and submit feces at the designated time and in an appropriate way.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Graft Versus Host Disease, Postbiotics, Butyrate
Keywords
butyrate, Graft Versus Host Disease, postbiotics

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭)
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Butyrate
Arm Type
Experimental
Arm Description
Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭ per day)
Intervention Type
Drug
Intervention Name(s)
sodium butyrate
Intervention Description
Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭, per day)
Primary Outcome Measure Information:
Title
Incidence of GVHD
Time Frame
through study completion, an average of 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients undergoing hematopoietic stem cell transplantation Adult patients over 19 years and under 70 of age Exclusion Criteria: Patients who did not agree to participate in the study If feces are not suitable for analysis
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Seug Yun Yoon, MD
Phone
+82 010-9267-2281
Email
ysy6496@schmc.ac.kr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jong-Ho Won, MD, PhD
Organizational Affiliation
Soonchunhyang University Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Soonchunhyang University Seoul Hospital
City
Seoul
ZIP/Postal Code
04401
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Seug Yun Yoon, MD
Phone
+82 010-9267-2281
Email
ysy6496@schmc.ac.kr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Intestinal Microbiome-based Research for the Prevention of Acute GVHD

We'll reach out to this number within 24 hrs